Systemic therapy for hepatocellular carcinoma

Seminars in Oncology

Volumn 28, Issue 5, 2001, Pages 514-520

  Leung, Thomas W T ^a,b   Johnson, Philip J ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CISPLATIN; CLOFAZIMINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; INTERFERON; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NOLATREXED; PACLITAXEL; SEMUSTINE; THALIDOMIDE; VINBLASTINE;

CANCER SURVIVAL; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL TIME; TREATMENT INDICATION;

EID: 0034793995     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90144-7     Document Type: Article

References (55)

1. Primary liver cancers in Japan
2. The surgical management of primary carcinoma of the liver
3. Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients
4. Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients
5. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis
6. Expression of P-glycoprotein in hepatocellular carcinoma: A potential marker of prognosis
7. Vinblastine in the treatment of carcinoma of the liver
8. Induction of remission in hepatocellular carcinoma with doxorubicin
9. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: Clinical and pharmacokinetic results
10. Induction of remission in hepatocellular carcinoma. A comparison of VP16 with Adriamycin
11. 4′-Epidoxorubicin (epirubicin): Activity in hepatocellular carcinoma
12. Mitozantrone as single agent therapy in hepatocellular carcinoma. A phase II study
13. A randomized phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma: An ECOG study
14. Phase II study of high dose ifosfamide in hepatocellular carcinoma
15. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients
16. A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma
17. A multi-centre randomized phase II study of Nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma
18. Phase II studies with daunoxome in patients with non-resectable hepatocellular carcinoma: Clinical and pharmacokinetic outcomes
19. Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer)
20. Phase II trial of thalomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC)
21. Clinical trials in primary hepatocellular carcinoma: Current status and future directions
22. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial
23. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma - An impossible meta-analysis?
24. Primary hepatocellular carcinoma in the Eastern Province of Saudi Arabia: Treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C
25. Primary liver cancer
26. Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: A Southeastern Cancer Study Group trial
27. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b
28. 5-Fluorouracil and d,l-leucovorin calcium are active to treat unresectable hepatocellular carcinoma patients: Preliminary results of a phase II study
29. Combined cis-platinum and alpha interferon therapy of advanced hepatocellular carcinoma
30. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: A phase II study
31. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma
32. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma
33. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
34. Chemotherapy in hepatocellular carcinoma
35. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication
36. Pre-operative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma
37. Patient characteristics that predict response and survival after systemic PIAF chemotherapy for inoperable hepatocellular carcinoma
38. Estrogen receptors in hepatocellular carcinoma
39. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma
40. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism
41. Prospective controlled trial with anti-estrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma
42. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
43. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial
44. Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial
45. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma
46. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial
47. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo
48. Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study
49. TNP-470 and recombinant human interferon-alpha2a inhibit angiogenesis synergistically
50. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
51. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: A prospective randomised trial
52. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: A randomized controlled trial
53. A prospective trial of recombinant human interferon-alpha 2b in previously untreated patients with hepatocellular carcinoma
54. Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma
55. Recombinant human gamma-interferon in primary hepatocellular carcinoma